Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
SMC Corp Stock Surges as Palliser Capital Pushes for Major Share Buyback 
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns 
Google Secures Pentagon AI Deal for Classified Projects 
U.S. Demand for Alternative Satellite Providers Remains Strong Amid SpaceX Regulatory Push 
Chinese Chip Stocks Surge on AI Boom and Domestic Tech Push 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
Toyota Global Vehicle Sales Decline in March Amid RAV4 Transition and Middle East Slowdown 
Nomura Shares Drop After Profit Miss Despite Strong Revenue Growth 
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
 - EconoTimes)
NEW YORK, May 04, 2017 -- Gainey McKenna & Egleston announces that a class action lawsuit has been filed against ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular” or the “Company”) (Nasdaq:IMUC) in the United States District Court for the Central District of California on behalf of purchasers of ImmunoCellular securities from May 1, 2012 through December 11, 2013, inclusive (the “Class Period”). The lawsuit seeks to recover damages for ImmunoCellular investors under the federal securities laws.
The Complaint alleges that that Defendants made false and misleading statements and/or failed to disclose that ImmunoCellular retained Lidingo Holdings, LLC to publish promotional articles designed to unlawfully promote ImmunoCellular, which led the market to believe that ImmunoCellular’s clinical studies for its product candidate ICT-107 was going well. As a result of this scheme, ImmunoCellular’s share price was artificially inflated. On April 10, 2017, the Securities and Exchange Commission announced enforcement actions against ImmunoCellular, as well as other individuals and entities, for engaging in stock promotion schemes
If you wish to serve as lead plaintiff, you must move the Court no later than June 30, 2017. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, or to discuss your rights or interests regarding this class action, please contact Thomas J. McKenna, Esq. or Gregory M. Egleston, Esq. of Gainey McKenna & Egleston at (212) 983-1300, or via e-mail at [email protected] or [email protected].
Please visit our website at http://www.gme-law.com for more information about the firm.
